Can a tailored chemo cocktail outsmart a common leukemia?

NCT ID NCT06529250

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial is testing whether a chemotherapy combination called HAD, given at intermediate doses, works better than the standard regimen for people with a specific genetic subtype of acute myeloid leukemia (AML) known as CEBPA double-mutated. The study enrolls adults aged 14 to 55 with this leukemia type. Participants receive either the HAD regimen or conventional treatment, and researchers compare how long they live without the disease returning or worsening.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A combination chemotherapy regimen called HAD, which includes homoharringtonine, cytarabine, and daunorubicin, given at intermediate doses.
What this could lead to: If successful, this could establish a more effective first-line chemotherapy for CEBPA double-mutated AML, potentially improving survival and reducing relapse.
What could go wrong: This is a mid-stage trial, and the benefits seen in earlier retrospective studies may not hold up. Chemotherapy carries significant side effects, and the regimen may not be better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia acute myeloid leukemia, biallelic CEBPA gene mutation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML

Contacts and locations

Locations

Blood Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.